Althea Technologies provides services that help drug developers speed up the drug discovery and testing process, as well as reduce risks and costs associated with research and development efforts. Founded in 1998 by co-chairs Francois Ferre and Magda Marquet -- who hold Ph.D.s in molecular oncology and biochemical engineering -- the company assists in the development process from discovery through testing, regulatory support, and contract manufacturing stages. Services include gene expression analysis, protein production, and therapeutic and vaccine product manufacturing for clinical trials.

The Whitehead Institute for Biomedical Research blazes new trails in bioscience. The organization, funded by both the public and private sectors, investigates such diseases as Parkinson's and cancer and dives into the depths of biology, genomics, and genetics to gain new understanding about disease and health. The Whitehead Institute contributed to the international effort to map the human genome, and is actively researching stem cells. Other achievements include discovering a system for multiplying adult stem cells and creating the first genetically defined human cancer cell. The institute was founded in 1982 by philanthropist Edwin "Jack" Whitehead and draws researchers from MIT.

Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production. The company develops microRNA-based diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumor of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other carcinomas in the lung and pleura. The company also focuses on the development of minimally/non-invasive, blood or serum-based molecular diagnostics tests. In addition, it develops microRNA-based therapeutic products for the treatment of liver cancer and chronic infections. The company has a license and collaboration agreement with Prometheus Laboratories Inc. to license and sublicense certain rights related to the company's microRNA-based cancer diagnostic tests; and a testing and administrative services agreement with Teva Pharmaceutical Industries Ltd. to distribute these tests in Turkey and Israel.

Nature's Sunshine Products, Inc. company was founded in 1972 and is based in Provo, Utah. Nature's Sunshine Products, Inc., together with its subsidiaries, engages in the manufacture and marketing of nutritional and personal care products worldwide. The company offers herbal products in the form of capsules or tablets; single herbs and herb combinations in the form of liquid herbs and extracts; vitamins and mineral supplements in the form of chewable or non-chewable tablets; personal care products, including oils and lotions, aloe vera gel, herbal shampoo, herbal skin treatment, toothpaste, and skin cleanser; and various other products, such as nutritional drinks, homeopathic products, and powders. Nature's Sunshine Products sells its products to a sales force of independent distributors and managers, who use the products themselves or resell them to other distributors or consumers. It also exports its products to various countries, including Argentina, Australia, Chile, New Zealand, and Norway.

LifeSpan BioSciences likes the way genes express themselves. The firm helps drugmakers develop new product candidates faster by finding proteins and RNA in human tissue samples to identify gene expression associated with disease. It licenses access to its databases of gene expressions and protein localizations to drug developers. Also available are target validation and tissue pathology services. LifeSpan's clients include pharmaceutical companies in Asia, Europe, and North America.

Marker Gene Technologies sells itself. The company offers drug researchers a variety of marker genes for monitoring gene expression, intracellular targeting, and other purposes. The company's marker genes are used in research for agricultural biotechnology, cell culturing, and bacteriology. Additional products include reagents, enzyme substrates and kits, and other molecular biology products. Marker Gene Technologies also maintains four fully equipped laboratories from which it provides contract research services for biotechnology and pharmaceutical clients. The firm markets its products through a number of distributors in the US and abroad, in Europe, Asia, and the Middle East.

Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California. Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Pharmacyclics's products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer.

Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

Cellectis SA company develops technologies involving the research and development of rational genome engineering (making changes in the genetics of a cell or organism). The company's research is primarily based on the Meganucleasus, a natural classification of DNA that isolates unique breaks at key locations within living cells. Its patented Meganuclease Recombination Systems technology helps to initiate the rational genome engineering process, which in turn can help treat diseases and augment genetic codes.

Centocor Ortho Biotech has ways of making your immune system behave itself. The Johnson & Johnson subsidiary makes blockbuster biotech drug Remicade, a monoclonal antibody used to treat a number of autoimmune conditions, or diseases in which the body's immune system attacks its own tissues. It is approved in the US and Europe for several indications, including Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis (a type of arthritis of the spine). The company also makes oncology drugs Doxil and Leustatin, and immunosuppressant Orthoclone for organ transplantation.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.